Is Isturisa (osilodrostat) patented?
Yes. Isturisa (osilodrostat) is protected by patents, including in the form of patents covering the drug substance and/or specific formulations and uses. Exactly which patents are listed and their expiry dates depend on the country and the specific authorization holders and national patent registers.
When does an Isturisa patent expire?
Patent expiry is jurisdiction-specific. The expiry date also depends on what kind of protection you mean: the basic drug patent, later “life-cycle” patents (for example, formulation or dosing-related claims), and any extensions tied to regulatory approval in that country. To answer precisely, you need the target market (for example, US vs EU vs UK vs a specific EU country) and the particular patent numbers listed there.
How do patents affect when generics or biosimilars could arrive?
If a generic manufacturer wants to market a product, it typically can only do so after relevant patent barriers expire or if it successfully challenges them or obtains a settlement/licence. The specific route differs by regulator and product type, but the practical effect is the same: patent status can delay market entry even after regulatory review pathways exist.
Where to check the exact Isturisa patent numbers for your country
Look up patents in:
- National patent databases for the jurisdiction you care about (for example, USPTO for the US, EPO national validation routes for parts of Europe, UKIPO for the UK).
- Patent linkage or “orange book” style sources where they exist in that country (these typically list marketed-drug patents and associated expiry information).
What you can do next to get the exact answer
Tell me the country/region you mean (for example, US, UK, Germany, France, or EU) and whether you want the expiry date for the original drug patent or any “secondary” patents. With that, I can narrow down which patents are most relevant to Isturisa’s market exclusivity in that specific place.
Sources
No sources were provided in the prompt.